Clinical data harmonization is the bottleneck for life sciences AI

A recent Pharmaceutical Executive commentary argues that clinical data harmonization is the real bottleneck standing between life sciences companies and AI's potential. That means restructuring how trial data is ingested, mapped and analyzed so it is ready for machine learning pipelines.

That puts the problem in plumbing more than in models. It lands on the head of clinical data management and on the CIO who funds that group. Their next decision is an architecture choice, and the models they're shopping for depend on it.

Budgets climbing, deployments lagging

Anbil's BioPharm International piece says the shift from AI experimentation to scale is particularly acute for mid-market developers, CDMOs and specialized biotech firms, which face a "Darwinian reset," while large pharmaceutical companies have the capital to invest broadly across the AI spectrum.

Where AI took hold first

The authors write that value is currently concentrated in specific, high-impact use cases. In biotech R&D, breakthrough applications have emerged where clean, verifiable data fits naturally into scientists' daily workflows.

Anbil and Tadikonda write that these breakthrough applications have emerged where clean, verifiable data integrates naturally into scientists' daily workflows. That suggests adoption tracks data readiness. The tool arrives where the inputs are already in order. A clinical operations leader deciding where to deploy AI next can use that pattern as a benchmark.

Five data streams, one trial

In a June commentary in Applied Clinical Trials, Anbil and Partha Khot set out the scope of the problem. One study can draw on electronic data capture for structured trial data, electronic health records for medical history, eCOA tools for patient-reported outcomes, wearables for continuous monitoring and high-resolution imaging. In the past, teams cleaned, mapped and harmonized all of that data by hand. The work was labor-intensive and error-prone, and it caused significant delays.

Anbil's BioPharm International piece says data scientists and clinical data managers within pharmaceutical SMEs often spend up to 80% of their time wrangling data rather than extracting actionable insights. That leaves little time for analysis.

The Applied Clinical Trials piece describes an architectural shift from warehouses to lakehouses. Clinical data warehouses were well governed and good for regulatory reporting, but they couldn't keep up with how fast and how varied modern data is. Data lakes scaled well but often turned into swamps without the provenance an FDA submission needs. According to the authors, comparative analyses of clinical data management architectures point to lakehouse models as the strongest option for AI initiatives. A lakehouse combines the strict governance of a warehouse with enough flexibility to handle unstructured data, including free-text clinical notes, high-resolution medical imaging and the continuous output of wearable sensors.

Automation is next. Commentary in Applied Clinical Trials says proof-of-concept models show that autonomous AI agents can ingest, profile and cleanse clinical data across sources such as EDC, CTMS and LIMS without manual ETL coding. The operative phrase is "proof of concept." The direction is clear. The size of the gain on any given study isn't known yet.

The case for faster returns

The phrase "at least one use case" reconciles the two. A single win in a contained workflow is one thing. Enterprise scale across many trials, each with its own mix of data sources, is where harmonization gets expensive. Parth Khanna, co-founder and CEO of ACTO, suggested a second ingredient in an interview with Pharmaceutical Executive published in August. He called trust the most important factor in any AI rollout and put it as an equation: trust equals compliant plus capable. His argument is that an agent that understands the specific role it supports, such as a medical science liaison's scope for scientific exchange, gets better on both counts at once. Clean data may be necessary without being enough.

Governance on the same timeline

Regulation adds pressure. Anbil and Tadikonda write that the FDA and the EU AI Act require life sciences leaders to balance speed with compliance, transparency and human oversight. Oversight depends on traceability, and that brings the lakehouse argument back to provenance, the thing data lakes lacked when a submission came due.